Core Insights - Peijia Medical-B (9996.HK) experienced a stock price increase of 8.26% to HKD 6.29, reaching a nearly two-month high since October 21 [1] - The company announced the approval of its TaurusTrio™ Transcatheter Aortic Valve (TAV) system by the National Medical Products Administration of China, with expectations for a successful market launch in China by December 11, 2025 [1] - The TaurusTrio™ TAV system aims to provide a safe and effective treatment option for Chinese patients suffering from severe aortic regurgitation (AR), addressing a significant unmet clinical need [1] - CEO and Chairman Zhang Yi has begun purchasing company shares in the open market since December 1, 2025, with a total investment not exceeding HKD 15 million, reflecting confidence in the company's intrinsic value and growth potential [1] Company Developments - The approval of the TaurusTrio™ TAV system is a significant milestone for Peijia Medical, as it seeks to fulfill a critical demand in the Chinese healthcare market [1] - Zhang Yi's share purchase indicates a strong belief in the company's future prospects and may signal potential further investments in the company [1]
沛嘉医疗-B涨超8% 股价创近2个月新高